AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01757366
Drug: First-line Chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
Trial: NCT01751802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Ecopipam
Trial: NCT01369355
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously.
Trial: NCT02436096
Drug: TNX-102 SL Tablet, 2.8mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
Trial: NCT02436096
Drug: Placebo SL Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
Trial: NCT02319759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
Trial: NCT02187848
Drug: SAR408701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
Trial: NCT00024167
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 IV, day 1 on Weeks 1, 3, 5
Trial: NCT01936909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01721577
Drug: AXL1717
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-1 receptor inhibitor
Trial: NCT01536288
Drug: Rhodiola crenulata
RxNorm normalized name: RHODIOLA CRENULATA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
Trial: NCT01536288
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
Trial: NCT03577171
Drug: ABI-H0731
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 300mg QD of ABI-H0731 tablets orally.
Trial: NCT03577171
Drug: SOC ETV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
Trial: NCT03577171
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching QD placebo tablets orally.
Trial: NCT04577352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered per schedule specified in the arm.
Trial: NCT03209830
Drug: OSU 6162
RxNorm normalized name: Osurnia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
Trial: NCT03209830
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
Trial: NCT01410695
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01410695
Drug: Placebo (methotrexate)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01410695
Drug: Placebo (masitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240084
Drug: nesiritide (Natrecor(TM))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of IV nesiritide
Trial: NCT01327638
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with SpA/AS who took etoricoxib
Trial: NCT01327638
Drug: nsNSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with SpA/AS who took nsNSAIDs
Trial: NCT00969059
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
Trial: NCT01281878
Drug: Vitamin B 6
RxNorm normalized name: vitamin B 6 100 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
Trial: NCT03479671
Drug: Intralipid, 20% Intravenous Emulsion
RxNorm normalized name: Intralipid, 20% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
Trial: NCT00304954
Drug: Oral Rapamycin
RxNorm normalized name: kanamycin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
Trial: NCT02626182
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill that looks like sildenafil tablets
Trial: NCT03578276
Drug: Prednisolone acetate 1% ophthalmic suspension
RxNorm normalized name: Prednisolone Acetate 1% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroidal anti-inflammatory
Trial: NCT03578276
Drug: Bromfenac 0.075% Oph Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory
Trial: NCT01911637
Drug: VBY-036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug VBY-036
Trial: NCT01911637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01406873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
Trial: NCT00781131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactulose placebo
Trial: NCT01907724
Drug: IDX719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX719 will be supplied as a 50 mg tablet for oral administration.
Trial: NCT01907724
Drug: TMC647055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC647055 will be supplied as 150 mg capsules for oral administration.
Trial: NCT00350519
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care based on the Institution's treatment policy.
Trial: NCT01676584
Drug: RO6811135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending doses sc
Trial: NCT01676584
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single doses sc
Trial: NCT00478361
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 40 mg/m\^2 IV over 20 minutes
Trial: NCT03066440
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
Trial: NCT02649608
Drug: 0.04 mg Lu AE04621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg dose group
Trial: NCT02649608
Drug: 0.2 mg Lu AE04621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg dose group
Trial: NCT02649608
Drug: 0.4 mg Lu AE04621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg dose group
Trial: NCT02649608
Drug: 0.6 mg Lu AE04621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg dose group
Trial: NCT02649608
Drug: 0.8 mg Lu AE04621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg dose group
Trial: NCT02649608
Drug: 1.0 mg Lu AE04621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg dose group
Trial: NCT02649608
Drug: 1.2 mg Lu AE04621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg dose group
Trial: NCT02883049
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02883049
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02883049
Drug: Hydrocortisone Sodium Succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT02883049
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT04602390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT02883049
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02883049
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT and IV
Trial: NCT03379675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
Trial: NCT00744211
Drug: 1mg/kg sitaxsentan sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
Trial: NCT02008656
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02008656
Drug: Capecitabine (Xeloda®)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04488107
Drug: FCN-437c
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
Trial: NCT03639571
Drug: Ibuprofen 200 mg TEPI Medicated Plaster
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
Trial: NCT04433143
Drug: Minocycline hydrochloride capsules were taken orally
RxNorm normalized name: minocycline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
Trial: NCT03512639
Drug: Homeopathic Medication
RxNorm normalized name: homeopathic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma
Trial: NCT03512639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
Trial: NCT01219049
Drug: Tyrosine
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg / day
Trial: NCT01219049
Drug: Tyrosine
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2000 mg / day
Trial: NCT01219049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily
Trial: NCT02235961
Drug: NNC9204-0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as single subcutaneous (s.c., under the skin) injections.
Trial: NCT02235961
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as single subcutaneous (s.c., under the skin) injections.
Trial: NCT02375724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
Trial: NCT00227344
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
Trial: NCT04152655
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets three times a day
Trial: NCT00429468
Drug: Vicodin® CR (extended-release hydrocodone/acetaminophen)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02603159
Drug: Capecitabine(Aibin)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
Trial: NCT04325035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
Trial: NCT04475939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered
Trial: NCT02749032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
Trial: NCT00822809
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg premedication
Trial: NCT03878472
Drug: SHR1210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
Trial: NCT00986154
Drug: low molecular weight heparin/unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment
Trial: NCT04637828
Drug: GNS561
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study drug
Trial: NCT00876798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
Trial: NCT01923168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (of BYL719 or BKM120) + Letrozole
Trial: NCT02764125
Drug: levodopa MR
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: levodopa MR/carbidopa/ODM-104
Trial: NCT03706898
Drug: Elpida®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elpida® capsules, 20mg
Trial: NCT04314310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equal volume of normal saline
Trial: NCT02567435
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and PO
Trial: NCT02876510
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide infusion
Trial: NCT03530917
Drug: RO7020531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.
Trial: NCT03530917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo hard capsules will be administered orally as per the dosing schedules described above.
Trial: NCT02166463
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03933319
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
Trial: NCT02166463
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04088604
Drug: LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
Trial: NCT02577432
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
Trial: NCT02577432
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
Trial: NCT05342532
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily
Trial: NCT04380324
Drug: LY3471851
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
Trial: NCT04380324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).
Trial: NCT01279590
Drug: PPD10558
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks
Trial: NCT01279590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules twice daily for 12 weeks
Trial: NCT00652691
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01500343
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram per day, during 3 months
Trial: NCT03344250
Drug: EGFR BATs with TMZ following SOC RT/TMZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
Trial: NCT03115060
Drug: intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
Trial: NCT03830762
Drug: Xanamem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
Trial: NCT03830762
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
Trial: NCT01889862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug placebo, self-administered daily
Trial: NCT03773094
Drug: Guava leaves extract
RxNorm normalized name: guava extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•
Trial: NCT00846170
Drug: co-biotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: give probiotic 2 t/day
Trial: NCT00846170
Drug: placebo 2T/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cross over of patients from study arm to placebo arm